Excited to see Synthekine initiate this study of #STK012. Important continued progress for the company, which has Canaan’s Julie Papanek Grant on its board.

Rondo Therapeutics has emerged from stealth mode with a bang. $67M Series A and ambitions to tackle solid tumors with next-gen #immunooncology platform. Round led by Canaan (Nina Kjellson) and Red Tree VC (Jon Edwards). PR from Rondo here: rondotx.com/news

Today, #Glooko announced the acquisition of DIABNEXT, a France-based company whose #DigitalHealth platform provides #diabetes #RemotePatientMonitoring and enhances physician-patient collaboration. Learn about Glooko XT, formerly DIABNEXT: bit.ly/3wfVPH4 #BetterTogether

Like Glooko's own platform, the mobile app from acquisition target DIABNEXT automatically takes in readings from continuous glucose monitors, insulin pumps and pens and other devices to help diabetes patients track daily health data. fiercebiotech.com/medtech/glooko…

At #ATTD2022, #Glooko will showcase its #diabetes data management and #RemotePatientMonitoring platform and industry leaders will share insights on #DigitalHealth. Experience our #ConnectedCare platform at stand 24B: bit.ly/3KKgmYW #BetterTogether

Glooko appoints Alfonso “Chito” Zulueta, former Eli Lilly & Company Senior Executive, to Board of Directors. glooko.com/news_reg/glook…

Welcoming Chito Zulueto and his deep expertise in diabetes care to the Glooko board! glooko.com/news_reg/glook…

Today, we welcome Alfonso "Chito" Zulueta to the #Glooko Board of Directors. Learn about his success at Former Account of Eli Lilly and Company in the pharmaceutical industry and the experience he brings as we continue to grow as a #DigitalHealth leader: bit.ly/3Lruk24 #BetterTogether

Lots of people talking about a string of negative data in biopharma… yes, there have been some notable upsets

Congrats to Julie and the Day One team! A new day for pediatric cancer patients: Day One's share price doubles on initial data for brain tumor drug fiercebiotech.com/biotech/new-da…

Thrilled to see Hyalex appear on Business Insider list of biotech startups to watch in next year. Excited to see what CEO @carl_vause and team accomplish. Wende Hutton Julie Papanek Grant Yeji Jesse Lee | 이예지 Read full piece with BI subscription at: businessinsider.com/list-top-biote…

Exciting to see OncoResponse's clinical supply agreement with Regeneron to evaluate #OR2805 in combination with Libtayo. We'll be closely watching the clinical evaluation of this combination. Canaan's Wende Hutton is on the OncoResponse board. oncoresponse.com/news-center/pr…

IDEAYA announces positive interim data from P2 trial of darovasertib and crizotinib synthetic lethal combo. Provides rational for potential registration-enabling study in metastatic uveal melanoma. Canaan’s Tim Shannon is chair of the IDEAYA board. media.ideayabio.com/2022-09-11-IDE…

Big day for PACT Pharma. Data from 1st study using #CRISPR to substitute a gene in patient’s immune cells to treat cancer presented at #SITC2022 and published in nature. Groundbreaking research paves way for cutting-edge therapies. pactpharma.com/news/pact-phar…

Excited to see Qlaris Bio’s co-founder and CMO, Barbara Wirostko, on Endpoints News Women in Biopharma ’22 list. She is helping guide the co's effort to develop innovative therapies for debilitating ophthalmic diseases. Canaan's Wende Hutton is on co's BOD. endpts.com/special-report…

We are now two weeks away from presenting at #AACR2023! #OncoResponse's poster will publicly introduce for the first time our preclinical data of dual-targeting antibodies for LILRB1 and LILRB2. The poster presentation will take place April 19th. AACR #EliteCancerResponders

Abyrx, Inc. announced additional FDA clearances for the company's MONTAGE® Settable, Resorbable Bone Putty as both a bone void filler and cranial bone cement, which follow the highly successful clinical introduction of MONTAGE use on bleeding bone. prnewswire.com/news-releases/…

AACR 2023 has begun! OncoResponse has a poster presentation on April 19th, which will publicly introduce for the first time preclinical data regarding our dual-targeting antibodies for LILRB1 and LILRB2. The poster will soon be available on our website. #EliteCancerResponders

CEO Clifford Stocks and CMO Bob Lechleider enjoying their time in Chicago at the ASCO annual meeting! #ASCO23 #EliteCancerResponders

Big Pharma has a model to make a profit and save lives. So, whats the hold-up? - Blog - Business in Global Society - Harvard Business School hbs.edu/bigs/blog/post…